These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 30865813)
21. Genetic, clinic and histopathologic characterization of BRCA-associated hereditary breast and ovarian cancer in southwestern Finland. Pallonen TA; Lempiäinen SMM; Joutsiniemi TK; Aaltonen RI; Pohjola PE; Kankuri-Tammilehto MK Sci Rep; 2022 Apr; 12(1):6704. PubMed ID: 35469032 [TBL] [Abstract][Full Text] [Related]
22. [Comparison of hereditary breast and ovarian cancer syndrome and sporadic ovarian cancer in ovarian cancer BRCA mutations]. Duan RR; Sun LX; Zhao HW Zhonghua Fu Chan Ke Za Zhi; 2021 Nov; 56(11):788-795. PubMed ID: 34823292 [No Abstract] [Full Text] [Related]
23. Ovarian cancer surveillance in the clinical follow up of women with known BRCA1 or BRCA2 pathogenic variants in a large health care system. Nañez A; Stram DA; Garcia C; Powell CB Gynecol Oncol; 2021 Oct; 163(1):134-141. PubMed ID: 34330534 [TBL] [Abstract][Full Text] [Related]
24. Transcriptome Patterns of Arakelyan A; Melkonyan A; Hakobyan S; Boyarskih U; Simonyan A; Nersisyan L; Nikoghosyan M; Filipenko M; Binder H Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33525353 [TBL] [Abstract][Full Text] [Related]
25. Expression and mutations of BRCA in breast cancer and ovarian cancer: Evidence from bioinformatics analyses. Wang Z; Zhang J; Zhang Y; Deng Q; Liang H Int J Mol Med; 2018 Dec; 42(6):3542-3550. PubMed ID: 30221688 [TBL] [Abstract][Full Text] [Related]
26. Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation. Kotsopoulos J; Gronwald J; Karlan B; Rosen B; Huzarski T; Moller P; Lynch HT; Singer CF; Senter L; Neuhausen SL; Tung N; Eisen A; Foulkes WD; Ainsworth P; Sun P; Lubinski J; Narod SA; Gynecol Oncol; 2018 Jul; 150(1):85-91. PubMed ID: 29793803 [TBL] [Abstract][Full Text] [Related]
27. A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention. Hanley GE; McAlpine JN; Miller D; Huntsman D; Schrader KA; Blake Gilks C; Mitchell G BMC Cancer; 2018 Mar; 18(1):254. PubMed ID: 29506471 [TBL] [Abstract][Full Text] [Related]
28. Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil. Maistro S; Teixeira N; Encinas G; Katayama ML; Niewiadonski VD; Cabral LG; Ribeiro RM; Gaburo Junior N; de Gouvêa AC; Carraro DM; Sabino EC; Diz MD; Chammas R; de Bock GH; Folgueira MA BMC Cancer; 2016 Dec; 16(1):934. PubMed ID: 27914478 [TBL] [Abstract][Full Text] [Related]
29. Evaluation of germline BRCA1 and BRCA2 mutations in a multi-ethnic Asian cohort of ovarian cancer patients. Hasmad HN; Lai KN; Wen WX; Park DJ; Nguyen-Dumont T; Kang PCE; Thirthagiri E; Ma'som M; Lim BK; Southey M; Woo YL; Teo SH Gynecol Oncol; 2016 May; 141(2):318-322. PubMed ID: 26541979 [TBL] [Abstract][Full Text] [Related]
30. Double PALB2 and BRCA1/BRCA2 mutation carriers are rare in breast cancer and breast-ovarian cancer syndrome families from the French Canadian founder population. Ancot F; Arcand SL; Mes-Masson AM; Provencher DM; Tonin PN Oncol Lett; 2015 Jun; 9(6):2787-2790. PubMed ID: 26137147 [TBL] [Abstract][Full Text] [Related]
31. Novel and recurrent BRCA2 mutations in Italian breast/ovarian cancer families widen the ovarian cancer cluster region boundaries to exons 13 and 14. Coppa A; Buffone A; Capalbo C; Nicolussi A; D'Inzeo S; Belardinilli F; Colicchia V; Petroni M; Granato T; Midulla C; Zani M; Ferraro S; Screpanti I; Gulino A; Giannini G Breast Cancer Res Treat; 2014 Dec; 148(3):629-35. PubMed ID: 25395318 [TBL] [Abstract][Full Text] [Related]
32. Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy. Schrader KA; Hurlburt J; Kalloger SE; Hansford S; Young S; Huntsman DG; Gilks CB; McAlpine JN Obstet Gynecol; 2012 Aug; 120(2 Pt 1):235-40. PubMed ID: 22776961 [TBL] [Abstract][Full Text] [Related]
33. Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer. Hyman DM; Zhou Q; Iasonos A; Grisham RN; Arnold AG; Phillips MF; Bhatia J; Levine DA; Aghajanian C; Offit K; Barakat RR; Spriggs DR; Kauff ND Cancer; 2012 Aug; 118(15):3703-9. PubMed ID: 22139894 [TBL] [Abstract][Full Text] [Related]
34. Peripheral blood DNA methylation detected in the BRCA1 or BRCA2 promoter for sporadic ovarian cancer patients and controls. Bosviel R; Michard E; Lavediaux G; Kwiatkowski F; Bignon YJ; Bernard-Gallon DJ Clin Chim Acta; 2011 Jul; 412(15-16):1472-5. PubMed ID: 21557934 [TBL] [Abstract][Full Text] [Related]
35. AURKA and BRCA2 expression highly correlate with prognosis of endometrioid ovarian carcinoma. Yang F; Guo X; Yang G; Rosen DG; Liu J Mod Pathol; 2011 Jun; 24(6):836-45. PubMed ID: 21441901 [TBL] [Abstract][Full Text] [Related]
37. Aurora kinase A promotes ovarian tumorigenesis through dysregulation of the cell cycle and suppression of BRCA2. Yang G; Chang B; Yang F; Guo X; Cai KQ; Xiao XS; Wang H; Sen S; Hung MC; Mills GB; Chang S; Multani AS; Mercado-Uribe I; Liu J Clin Cancer Res; 2010 Jun; 16(12):3171-81. PubMed ID: 20423983 [TBL] [Abstract][Full Text] [Related]
38. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age. van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502 [TBL] [Abstract][Full Text] [Related]
39. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. McLaughlin JR; Risch HA; Lubinski J; Moller P; Ghadirian P; Lynch H; Karlan B; Fishman D; Rosen B; Neuhausen SL; Offit K; Kauff N; Domchek S; Tung N; Friedman E; Foulkes W; Sun P; Narod SA; Lancet Oncol; 2007 Jan; 8(1):26-34. PubMed ID: 17196508 [TBL] [Abstract][Full Text] [Related]